AA
NVO

Altrafin AG’s Novo Nordisk NVO Stock Holding History

Altrafin AG’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.71M Sell
139,963
-34,450
-20% -$1.48M 2.63% 14
2026
Q1 		$6.41M Sell
174,413
-770
-0.4% -$36.5K 2.21% 16
2025
Q4 		$8.91M Sell
175,183
-72,922
-29% -$3.73M 2.83% 14
2025
Q3 		$13.8M Buy
248,105
+19,706
+9% +$1.15M 4.36% 8
2025
Q2 		$15.8M Buy
228,399
+39,816
+21% +$2.71M 5.32% 5
2025
Q1 		$13.1M Buy
188,583
+52,137
+38% +$4.31M 5.09% 6
2024
Q4 		$11.7M Buy
136,446
+37,151
+37% +$4.02M 4.07% 8
2024
Q3 		$11.8M Buy
99,295
+42,668
+75% +$5.69M 4.26% 8
2024
Q2 		$8.08M Sell
56,627
-3
-0% -$398 2.99% 13
2024
Q1 		$7.27M Buy
56,630
+19
+0% +$2.26K 2.64% 14
2023
Q4 		$5.86M Sell
56,611
-2,161
-4% -$214K 2.26% 17
2023
Q3 		$5.34M Buy
58,772
+3,350
+6% +$295K 2.33% 17
2023
Q2 		$4.48M Sell
55,422
-138
-0.2% -$11.3K 2.01% 18
2023
Q1 		$4.42M Sell
55,560
-11,818
-18% -$838K 2.17% 19
2022
Q4 		$4.56M Buy
67,378
+1,492
+2% +$87.5K 2.67% 12
2022
Q3 		$3.28M Buy
65,886
+1,468
+2% +$78.6K 1.97% 21
2022
Q2 		$3.59M Sell
64,418
-15,012
-19% -$833K 1.94% 20
2022
Q1 		$4.41M Buy
79,430
+10,876
+16% +$558K 1.73% 24
2021
Q4 		$3.84M Buy
+68,554
New +$3.71M 1.39% 26

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Altrafin AG's NVO Position: Q2 2026 in Review

Altrafin AG reduced its Novo Nordisk (NVO) stake by 20% in Q2 2026, selling an estimated $1.48M and leaving 139,963 shares worth $6.71M. The position accounts for 2.63% of the portfolio, ranked #14.

Altrafin AG first reported a position in NVO in Q4 2021 and has held it in 19 quarters since. The position peaked at $15.8M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Altrafin AG held 139,963 shares of Novo Nordisk worth $6.71M as of Q2 2026.
  • Altrafin AG sold 34,450 Novo Nordisk shares in Q2 2026, an estimated $1.48M.
  • Novo Nordisk made up 2.63% of Altrafin AG's portfolio in Q2 2026, its #14 holding.
  • Altrafin AG first reported a position in Novo Nordisk in Q4 2021 and has held it in 19 quarters since.
  • Altrafin AG's Novo Nordisk position peaked at $15.8M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Altrafin AG's 13F filing for Q2 2026, filed 15 Jul 2026.